{"id":"NCT01993888","sponsor":"Ethicon, Inc.","briefTitle":"The EVARREST® Fibrin Sealant Patch Liver Study","officialTitle":"A Phase III Randomized, Controlled, Superiority Study Evaluating EVARREST® Fibrin Sealant Patch Versus Standard of Care Treatment in Controlling Parenchymal Bleeding During Hepatic Surgery","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-10","primaryCompletion":"2014-07","completion":"2014-09","firstPosted":"2013-11-25","resultsPosted":"2016-07-11","lastUpdate":"2016-07-11"},"enrollment":102,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hemorrhage"],"interventions":[{"type":"BIOLOGICAL","name":"EVARREST® Fibrin Sealant Patch","otherNames":[]},{"type":"OTHER","name":"Standard of Care (SoC)","otherNames":[]}],"arms":[{"label":"EVARREST® Fibrin Sealant Patch","type":"EXPERIMENTAL"},{"label":"Standard of Care (SoC)","type":"OTHER"}],"summary":"To evaluate the safety and hemostatic effectiveness of EVARREST® Fibrin Sealant Patch (EVARREST) versus standard of care treatment (SoC) in controlling parenchymal bleeding during hepatic surgery.","primaryOutcome":{"measure":"Hemostasis at the Target Bleeding Site (TBS) at 4-minutes Following Randomization","timeFrame":"Intraoperative, 4 minutes following randomization","effectByArm":[{"arm":"EVARREST™ Fibrin Sealant Patch","deltaMin":48,"sd":null},{"arm":"Standard of Care (SoC)","deltaMin":24,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":11},"locations":{"siteCount":17,"countries":["United States","Australia","New Zealand","United Kingdom"]},"refs":{"pmids":["27017161","26636489"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":12,"n":50},"commonTop":["Nausea","Constipation","Hypotension","Vomiting","Pyrexia"]}}